144 related articles for article (PubMed ID: 38101901)
1. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
McGarry A; Rosanbalm S; Leinonen M; Olanow CW; To D; Bell A; Lee D; Chang J; Dubow J; Dhall R; Burdick D; Parashos S; Feuerstein J; Quinn J; Pahwa R; Afshari M; Ramirez-Zamora A; Chou K; Tarakad A; Luca C; Klos K; Bordelon Y; St Hiliare MH; Shprecher D; Lee S; Dawson TM; Roschke V; Kieburtz K
Lancet Neurol; 2024 Jan; 23(1):37-45. PubMed ID: 38101901
[TBL] [Abstract][Full Text] [Related]
2. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Athauda D; Maclagan K; Skene SS; Bajwa-Joseph M; Letchford D; Chowdhury K; Hibbert S; Budnik N; Zampedri L; Dickson J; Li Y; Aviles-Olmos I; Warner TT; Limousin P; Lees AJ; Greig NH; Tebbs S; Foltynie T
Lancet; 2017 Oct; 390(10103):1664-1675. PubMed ID: 28781108
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 receptor agonists for Parkinson's disease.
Mulvaney CA; Duarte GS; Handley J; Evans DJ; Menon S; Wyse R; Emsley HC
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012990. PubMed ID: 32700772
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C;
Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606
[TBL] [Abstract][Full Text] [Related]
5. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Giladi N; Alcalay RN; Cutter G; Gasser T; Gurevich T; Höglinger GU; Marek K; Pacchetti C; Schapira AHV; Scherzer CR; Simuni T; Minini P; Sardi SP; Peterschmitt MJ
Lancet Neurol; 2023 Aug; 22(8):661-671. PubMed ID: 37479372
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.
Espay AJ; Stocchi F; Pahwa R; Albanese A; Ellenbogen A; Ferreira JJ; Giladi N; Gurevich T; Hassin-Baer S; Hernandez-Vara J; Isaacson SH; Kieburtz K; LeWitt PA; Lopez-Manzanares L; Olanow CW; Poewe W; Sarva H; Yardeni T; Adar L; Salin L; Lopes N; Sasson N; Case R; Rascol O;
Lancet Neurol; 2024 May; 23(5):465-476. PubMed ID: 38499015
[TBL] [Abstract][Full Text] [Related]
8. Trial of Lixisenatide in Early Parkinson's Disease.
Meissner WG; Remy P; Giordana C; Maltête D; Derkinderen P; Houéto JL; Anheim M; Benatru I; Boraud T; Brefel-Courbon C; Carrière N; Catala H; Colin O; Corvol JC; Damier P; Dellapina E; Devos D; Drapier S; Fabbri M; Ferrier V; Foubert-Samier A; Frismand-Kryloff S; Georget A; Germain C; Grimaldi S; Hardy C; Hopes L; Krystkowiak P; Laurens B; Lefaucheur R; Mariani LL; Marques A; Marse C; Ory-Magne F; Rigalleau V; Salhi H; Saubion A; Stott SRW; Thalamas C; Thiriez C; Tir M; Wyse RK; Benard A; Rascol O;
N Engl J Med; 2024 Apr; 390(13):1176-1185. PubMed ID: 38598572
[TBL] [Abstract][Full Text] [Related]
9. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
[TBL] [Abstract][Full Text] [Related]
10. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial.
van der Kolk NM; de Vries NM; Kessels RPC; Joosten H; Zwinderman AH; Post B; Bloem BR
Lancet Neurol; 2019 Nov; 18(11):998-1008. PubMed ID: 31521532
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
Soileau MJ; Aldred J; Budur K; Fisseha N; Fung VS; Jeong A; Kimber TE; Klos K; Litvan I; O'Neill D; Robieson WZ; Spindler MA; Standaert DG; Talapala S; Vaou EO; Zheng H; Facheris MF; Hauser RA
Lancet Neurol; 2022 Dec; 21(12):1099-1109. PubMed ID: 36402160
[TBL] [Abstract][Full Text] [Related]
14. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial.
Hauser RA; Cantillon M; Pourcher E; Micheli F; Mok V; Onofrj M; Huyck S; Wolski K
Lancet Neurol; 2011 Mar; 10(3):221-9. PubMed ID: 21315654
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.
NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators
Lancet Neurol; 2015 Aug; 14(8):795-803. PubMed ID: 26116315
[TBL] [Abstract][Full Text] [Related]
16. Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.
Chaudhuri KR; Odin P; Ferreira JJ; Antonini A; Rascol O; Kurtis MM; Storch A; Bannister K; Soares-da-Silva P; Costa R; Magalhães D; Rocha JF
BMC Neurol; 2022 Mar; 22(1):88. PubMed ID: 35279112
[TBL] [Abstract][Full Text] [Related]
17. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C
Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC
Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911
[TBL] [Abstract][Full Text] [Related]
19. Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study.
Vitek JL; Jain R; Chen L; Tröster AI; Schrock LE; House PA; Giroux ML; Hebb AO; Farris SM; Whiting DM; Leichliter TA; Ostrem JL; San Luciano M; Galifianakis N; Verhagen Metman L; Sani S; Karl JA; Siddiqui MS; Tatter SB; Ul Haq I; Machado AG; Gostkowski M; Tagliati M; Mamelak AN; Okun MS; Foote KD; Moguel-Cobos G; Ponce FA; Pahwa R; Nazzaro JM; Buetefisch CM; Gross RE; Luca CC; Jagid JR; Revuelta GJ; Takacs I; Pourfar MH; Mogilner AY; Duker AP; Mandybur GT; Rosenow JM; Cooper SE; Park MC; Khandhar SM; Sedrak M; Phibbs FT; Pilitsis JG; Uitti RJ; Starr PA
Lancet Neurol; 2020 Jun; 19(6):491-501. PubMed ID: 32470421
[TBL] [Abstract][Full Text] [Related]
20. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
Wei Q; Tan Y; Xu P; Tao E; Lu Z; Pan X; Wang B; Liu C; Dong X; Tian Y; Sun X; Cattaneo C; Chen S; Shang H;
CNS Drugs; 2022 Nov; 36(11):1217-1227. PubMed ID: 36346534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
